Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes-Reference-Cited by-同舟云学术

Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes

Published:2016 Issue:3 Volume:63 Page:263-273
ISSN:0918-8959
Container-title:Endocrine Journal
language:en
Short-container-title:Endocr J

Author:

Onishi Yukiko¹,Oura Tomonori²,Nishiyama Hiroshi²,Ohyama Sumika²,Takeuchi Masakazu²,Iwamoto Noriyuki²

Affiliation:

1. The Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan

2. Eli Lilly Japan K.K., Kobe, Japan

Publisher

Japan Endocrine Society

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.jstage.jst.go.jp/article/endocrj/63/3/63_EJ15-0518/_pdf

Reference21 articles.

1. 1. American Diabetes Association (2015) Approaches to glycemic treatment. Diabetes Care 38 (Suppl 1): S41-48.

2. 2. Japan Diabetes Society (2013) Treatment guide for diabetes. Available at http://www.jds.or.jp/common/fckeditor/editor/filemanager/connectors/php/transfer.php?file=/uid000025_54726561746D656E745F47756964655F666F725F44696162657465735F323031322D323031332E706466. Accessed 18 June 2015.

3. 3. Glaesner W, Vick AM, Millican R, Ellis B, Tschang SH, et al. (2010) Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev 26: 287-296.

4. 4. Trulicity [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company 2015. Available at http://pi.lilly.com/us/trulicity-uspi.pdf. Accessed 18 June 2015.

5. 5. Trulicity [Summary of Product Characteristics]. Houten, The Netherlands: Eli Lilly and Company 2015. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002825/WC500179470.pdf. Accessed 10 July 2015.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of baseline characteristics on the efficacy of dulaglutide added to basal insulin in Chinese patients with type 2 diabetes: A subgroup analysis of AWARD‐CHN3;Diabetes, Obesity and Metabolism;2024-01-07

2. Safety and effectiveness of dulaglutide 0.75 mg in Japanese patients with type 2 diabetes in real‐world clinical practice: 36 month post‐marketing observational study;Journal of Diabetes Investigation;2022-11-11

3. Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care;Journal of Personalized Medicine;2022-03-13

4. Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials;Journal of Diabetes Investigation;2022-03-03

5. Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study;Scientific Reports;2022-01-07